EP Wealth Advisors LLC Sells 1,190 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

EP Wealth Advisors LLC reduced its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 4.7% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 23,952 shares of the company’s stock after selling 1,190 shares during the quarter. EP Wealth Advisors LLC’s holdings in Teva Pharmaceutical Industries were worth $528,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Diversify Advisory Services LLC increased its position in Teva Pharmaceutical Industries by 2.5% during the 4th quarter. Diversify Advisory Services LLC now owns 20,355 shares of the company’s stock valued at $426,000 after purchasing an additional 496 shares during the period. Thrivent Financial for Lutherans increased its position in Teva Pharmaceutical Industries by 0.3% during the 4th quarter. Thrivent Financial for Lutherans now owns 225,210 shares of the company’s stock valued at $4,964,000 after purchasing an additional 699 shares during the period. Townsquare Capital LLC increased its position in Teva Pharmaceutical Industries by 2.1% during the 4th quarter. Townsquare Capital LLC now owns 40,162 shares of the company’s stock valued at $885,000 after purchasing an additional 812 shares during the period. Metis Global Partners LLC increased its position in Teva Pharmaceutical Industries by 6.7% during the 4th quarter. Metis Global Partners LLC now owns 13,697 shares of the company’s stock valued at $302,000 after purchasing an additional 860 shares during the period. Finally, Quadrant Capital Group LLC increased its position in Teva Pharmaceutical Industries by 27.7% during the 4th quarter. Quadrant Capital Group LLC now owns 4,377 shares of the company’s stock valued at $96,000 after purchasing an additional 949 shares during the period. 54.05% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on TEVA shares. Barclays reduced their price objective on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a research report on Thursday, January 30th. UBS Group reduced their target price on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a research report on Thursday, January 30th. Piper Sandler upped their target price on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a research report on Friday, January 17th. Hsbc Global Res raised shares of Teva Pharmaceutical Industries to a “strong-buy” rating in a research report on Monday, April 28th. Finally, Bank of America upped their target price on shares of Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the stock a “buy” rating in a research report on Thursday. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Buy” and an average price target of $23.71.

Teva Pharmaceutical Industries Stock Down 6.3%

NYSE:TEVA opened at $16.94 on Monday. Teva Pharmaceutical Industries Limited has a 1-year low of $12.47 and a 1-year high of $22.80. The firm’s 50-day moving average price is $15.18 and its 200-day moving average price is $17.44. The company has a market capitalization of $19.21 billion, a PE ratio of -11.68, a P/E/G ratio of 1.44 and a beta of 0.62. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings data on Wednesday, May 7th. The company reported $0.52 EPS for the quarter, beating the consensus estimate of $0.47 by $0.05. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. The company had revenue of $3.89 billion for the quarter, compared to the consensus estimate of $3.99 billion. During the same period in the prior year, the firm posted $0.48 EPS. Teva Pharmaceutical Industries’s revenue for the quarter was up 1.9% on a year-over-year basis. On average, equities analysts predict that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current fiscal year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.